Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Articles published by Genentech
< Previous
1
2
3
Next >
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
July 18, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study
July 17, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
July 17, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)
July 08, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
July 05, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
July 04, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 15, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
June 07, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
May 29, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
May 21, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
May 16, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
April 18, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
April 17, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
April 15, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies
February 25, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
February 16, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)
February 01, 2024
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
December 19, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
December 10, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
December 09, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
December 08, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
December 08, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
December 05, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development
November 21, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
October 27, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
October 18, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis
October 13, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided
October 12, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
October 11, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
October 11, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.